Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.
Like many rare diseases, fibrolamellar hepatocellular carcinoma (FLC) mounts a ferocious attack against an unlucky few-in this case, children, adolescents, and young adults.
help explain why immune cells behave differently in different tumor environments and offer several new molecular targets for improving liver cancer treatment and immunotherapy. “How do organ ...
The number of people dying from liver cancer has nearly doubled in the past two decades and is projected to keep rising, new analysis shows, despite around half of cases being preventable.